Together with the laboratories of Bernd Wollscheid and Berend Snijder at the ETH Zurich we investigate the proteome and the response to drug libraries of samples from patients with myeloproliferative neoplasms. In our project we aim at identifying pathways unaffected by standard therapies, but vulnerable to alternative therapeutic approaches.

Our group is also part of the acute myeloid leukemia tumor profiler consortium which comprises multiple “Omics”-technologies and drug screening platforms. This initiative aims at identifying active therapeutic compounds in patients with relapsed/refractory disease and ultimately implement them into clinical practice.

Very recently, we also established a diagnostic-clinical unit for individuals with clonal hematopoiesis of indeterminate potential (CHiP) in the diagnostic laboratory of hematology at the University Hospital Zurich. This technology may allow to identify individuals at risk for the development of hemato-oncological or cardiovascular disease.